In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014–2019)
Journal of Antimicrobial Chemotherapy · 02.08.2023 · 78 (8) · 2019-2027
DOI: 10.1093/jac/dkad200 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 03.07.2023. Verfasst von Miki Takemura und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd., Osaka, Japan. Hauptthemen laut MEDLINE: Cephalosporins, Anti-Bacterial Agents. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Shionogi.
Abstract (Originalsprache)
Objectives
To evaluate the in vitro antibacterial activity of cefiderocol, a siderophore cephalosporin against MBL-producing clinical isolates.
Methods
MBL-producing strains were selected from clinical isolates of Enterobacterales, Pseudomonas aeruginosa and Acinetobacter baumannii complex collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies from 2014 to 2019. MICs of cefiderocol and comparator agents were determined by the broth microdilution method according to the CLSI guideline.
Results
A total of 452 MBL-producing strains consisting of 200 Enterobacterales, 227 P. aeruginosa and 25 A. baumannii complex were identified. The highest number of MBL-producing Enterobacterales strains were detected in Greece. MBL-producing strains of both P. aeruginosa and A. baumannii complex were isolated most frequently in Russia. For Enterobacterales, 91.5% or 67.5% of MBL-producing strains had cefiderocol MIC values ≤4 mg/L (CLSI susceptibility breakpoint) or ≤2 mg/L (EUCAST susceptibility breakpoint), respectively. All MIC values of cefiderocol for MBL-producing P. aeruginosa strains were ≤4 mg/L (CLSI susceptibility breakpoint), and 97.4% of them had cefiderocol MIC values ≤2 mg/L (EUCAST susceptibility breakpoint). For A. baumannii complex, 60.0% or 44.0% of MBL-producing strains had cefiderocol MIC values ≤4 mg/L (CLSI susceptibility breakpoint) or ≤2 mg/L (EUCAST pharmacokinetic-pharmacodynamic susceptibility breakpoint), respectively. Against all types of MBL-producing strains, MIC distribution curves of cefiderocol were located in the lowest numerical values, compared with other β-lactams and β-lactam/β-lactamase inhibitor combinations tested and ciprofloxacin.
Conclusions
Although the types of MBL-producing strains isolated by country varied, cefiderocol showed potent in vitro activity against all types of MBL-producing Gram-negative bacteria regardless of the bacterial species.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd., Osaka, Japan.
- International Health Management Associates, Inc., Schaumburg, IL, USA.
Förderung
- Shionogi
Zitieren
APA
Takemura, M., Wise, M. G., Hackel, M. A., Sahm, D. F., & Yamano, Y. (2023). In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014–2019). Journal of Antimicrobial Chemotherapy, 78(8), 2019-2027. https://doi.org/10.1093/jac/dkad200
Vancouver
Takemura M, Wise MG, Hackel MA, Sahm DF, Yamano Y. In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014–2019). Journal of Antimicrobial Chemotherapy. 2023;78(8):2019-2027. doi:10.1093/jac/dkad200
BibTeX
@article{Takemura2023,
author = {Takemura, Miki and Wise, Mark G and Hackel, Meredith A and Sahm, Daniel F and Yamano, Yoshinori},
title = {In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014–2019)},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2023},
volume = {78},
number = {8},
pages = {2019--2027},
doi = {10.1093/jac/dkad200}
}
EUVIMED